| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10745566 | Parkinsonism & Related Disorders | 2014 | 7 Pages |
Abstract
IPX066 provided significant clinical benefits at the three dosages tested compared to placebo and was well tolerated in levodopa-naive PD patients. Of the dosages tested, IPX066 145Â mg TID appeared to provide the best overall balance between efficacy and safety.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Rajesh Pahwa, Kelly E. Lyons, Robert A. Hauser, Stanley Fahn, Joseph Jankovic, Emmanuelle Pourcher, Ann Hsu, Martin O'Connell, Sherron Kell, Suneel Gupta, APEX-PD Investigators APEX-PD Investigators,